|
External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial. |
|
|
Employment - 21st Century Oncology |
Leadership - 21st Century Oncology |
Consulting or Advisory Role - Bayer; Blue Earth Diagnostics; Dendreon; Ferring; Medivation |
Speakers' Bureau - Bayer; Dendreon; Medivation |
Research Funding - Bayer; Dendreon |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; Takeda |
Consulting or Advisory Role - Bayer; BN ImmunoTherapeutics; Janssen |
Research Funding - Bayer (Inst) |
|
|
|
|
|
Travel, Accommodations, Expenses - Bayer |
|
|
Consulting or Advisory Role - Bayer; Bayer |
Research Funding - Bayer; Bayer |